Before April 2026, investor sentiment surrounding Tesla Inc. was mixed, with many anticipating a rebound in the company’s stock price. However, recent performance has shown a troubling trend, with Tesla shares falling 13.9% in the month leading up to April 10, 2026, and down 21.6% year-to-date.
In a decisive move, Cathie Wood’s Ark Invest purchased 33,210 shares of Tesla, valued at approximately $11.4 million. This acquisition has sparked discussions among investors, particularly given the backdrop of Tesla’s declining stock performance.
The immediate effect of this purchase is twofold. For Ark Invest, this reflects a strong commitment to Tesla, aligning with Wood’s long-term bullish outlook on the electric vehicle market. Conversely, the market’s reaction to this investment may be cautious, given Tesla’s recent struggles.
Moreover, this investment comes at a time when Ark Invest is also heavily invested in CRISPR Therapeutics, which constitutes 6.6% of the Ark Innovation ETF. Last year, CRISPR Therapeutics reported a staggering loss of $664.6 million, raising concerns about its financial health and future prospects.
In 2024, CRISPR Therapeutics faced significant challenges, with only 5 out of 54 patients infused with their final product, Casgevy, after undergoing stem cell collection. This lack of successful outcomes has put additional pressure on the company’s stock and, by extension, on Ark Invest’s portfolio.
Experts suggest that Wood’s strategy may hinge on the belief that both Tesla and CRISPR Therapeutics will ultimately recover and thrive in their respective markets. However, the current financial data paints a concerning picture for both companies.
As investors assess the implications of Wood’s latest move, the contrast between her optimistic outlook and the harsh realities of the market raises questions. Will her faith in these companies pay off, or will the ongoing declines overshadow her investment strategy?
Details remain unconfirmed regarding any potential changes in Ark Invest’s overall strategy following this significant purchase. Investors will be watching closely to see how this decision impacts both Tesla and CRISPR Therapeutics in the coming months.
